Genome Editing/Genome Engineering Market Size, Share & Trends Analysis By Product & Service, By Application, By Technology, By End-Users, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Genome Editing/Genome Engineering Market Size, Share & Trends Analysis By Product & Service, By Application, By Technology, By End-Users, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Global Genome Editing/Genome Engineering Market is projected to be worth USD 25.3 billion by 2030

According to SPER Market Research, the Genome Editing/Genome Engineering Market is estimated to reach USD 25.3 billion by 2030 with a CAGR of 19.5%. Academies & government research centre used genome engineering before, now it is diversified into clinical & diagnostic fields too, this leads to the escalation of the market.

Impact of COVID-19 on the Genome Editing/Genome Engineering Market

The outbreak of COVID-19 has boosted the investment of pharmaceutical companies and biopharmaceutical companies, and genomic market player in research & development and in vaccine.

Scope of the report:

Market size available for years
2019-2030

Base year considered

2021

Forecast period

2022-2030

Segments covered

By Product & Service, By Application, By Technology, By End Users, By Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

Agilent Technologies, Beam Therapeutics, Bluebird Bio, Caribou Biosciences., Cellectis S.A, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, GenScript, Integrated DNA Technologies, Intellia Therapeutics, Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Precision Biosciences, Recombinetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Synthego, Tecan Life Sciences, Thermo Fisher Scientific, Transposagen, Biopharmaceuticals, Vigene Biosciences

Driver:Increase in funding

In the recent years there is increase in the government funding globally in the genomic research this allows academies & research centre to work on genomic engineering.

Restraints:Off-target effect of CRISPR Technology

CRISPR-Cas9 has an Off-target effects, The mismatch tolerance capacity of CRISPR-Cas9 is one to three, beyond this leads to off-target nuclease activity; it can be the reason for mutations in these genes in turn oncogenesis.

Opportunity: widespread use of Genome Engineering

Due to better efficacy, compliance, economical, optimization of therapy the demand for personalized medicine increasing worldwide. Personalized medicine markets offering lots of opportunities to the genomic market.

Challenges:Costly equipment

At the beginning, this might be costly for the academic research to afford, but in later stage the advanced technology is going to build affordable instruments, so it is a short term challenges for this market.

Global Genome Editing/Genome Engineering Market, by Product & Service: Based on the Product & Service, Global Genome Editing/Genome Engineering Market is segmented as; Reagents & consumables, Services, Software & systems

Global Genome Editing/Genome Engineering Market, by Application:

Based on the Application, Global Genome Editing/Genome Engineering Market is segmented as; Cell Line Engineering, Diagnostic applications, Drug discovery & development, Genetic Engineering, Other applications

Global Genome Editing/Genome Engineering Market, by Technology:

Based on the Technology, Global Genome Editing/Genome Engineering Market is segmented as; Antisense, CRISPR, TALEN, ZFN, Other technologies.

Global Genome Editing/Genome Engineering Market, by End-Users:

Based on the End-Users, Global Genome Editing/Genome Engineering Market is segmented as; Academic & Government Research Institutes, Biotechnology companies, Pharmaceutical companies.

Global Genome Editing/Genome Engineering Market, by Region:

North America owns the prime share of this market; it is because of growing exploitation of genetically modified crops, gene therapy, government grants and funding.